MEDI 570

Drug Profile

MEDI 570

Latest Information Update: 17 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Japan Tobacco
  • Developer MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Inducible T-cell co-stimulator protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Systemic lupus erythematosus

Most Recent Events

  • 17 Aug 2015 National Institute of Cancer (Canada) plans a phase I trial for Peripheral T-cell lymphoma (Second-line therapy or greater) in Canada (NCT02520791)
  • 31 Dec 2012 Discontinued - Phase-I for Systemic lupus erythematosus in Canada (SC)
  • 31 Dec 2012 Discontinued - Phase-I for Systemic lupus erythematosus in Mexico (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top